<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        33-5223-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ONDRON 2MG/ML AMPOULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ONDANSETRON
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        56.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="INTAS PHARMACEUTICALS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            INTAS PHARMACEUTICALS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Accord Healthcare Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A04AA01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ondron contains the active substance Ondansetron, which<br />belongs to a group of medicines called antiemetics.<br />Ondron is used for<br />&bull; Preventing nausea (feel sick) and vomiting (be sick) caused by<br />&minus; chemotherapy for cancer in adults and in children aged<br />&ge; 6 months<br />&minus; radiotherapy for cancer in adults only<br />&bull; Preventing and treatment of nausea and vomiting after<br />surgery in adults and in children aged &ge; 1 month.<br />Ask your doctor, nurse or pharmacist if you would like any<br />further explanation about these uses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Ondron if you are<br />&bull; allergic to Ondansetron or any of the other ingredients of<br />this medicine (listed in Section 6) or to any similar<br />medicines e.g. Granisetron or Dolasetron.<br />&bull; taking Apomorphine (a medicine used to treat Parkinson&rsquo;s<br />disease)<br />Warnings and precautions<br />Talk to your doctor, pharmacist or nurse before using Ondron<br />&bull; if you have a blockage in your gut or suffer from severe<br />constipation Ondansetron can make these conditions worse<br />&bull; if you have liver problems<br />&bull; if you have ever had problem with your heart or are taking<br />medicines used to treat heart problems (e.g. congestive<br />heart failure which causes shortness of breath and swollen<br />ankles)<br />&bull; if you have an uneven heart beat (arrhythmias)<br />&bull; if you are allergic to medicines similar to Ondansetron,<br />such as Granisetron or Palonosetron<br />&bull; if you are having surgery to remove your tonsils, because<br />treatment with Ondansetron may hide symptoms of internal<br />bleeding<br />&bull; if you have problems with the levels of salts in your blood,<br />such as Potassium, Sodium and Magnesium<br />If you are not sure if any of the above apply to you, talk to<br />your doctor, nurse or pharmacist before having Ondron.<br />Other medicines and Ondron<br />Tell your doctor or pharmacist if you are taking, have<br />recently taken or might take any other medicines, natural<br />supplements or vitamins or minerals.<br />In particular, tell your doctor, nurse or pharmacist if you are<br />taking any of the following medicines:<br />&bull; Phenytoin (used to treat epilepsy &amp; heart arrhythmias)<br />&bull; Carbamazepine (used to treat epilepsy &amp; neuralgic pain)<br />&bull; Rifampicin used to treat infections such as tuberculosis<br />(TB)<br />&bull; Antibiotics such as Erythromycin or Ketoconazole<br />&bull; Anti-arrhythmic medicines (used to treat an uneven heart<br />beat) such as Amiodarone<br />&bull; Beta-blocker medicines used to treat certain heart or eye<br />problems, anxiety or prevent migraines such as Atenolol or<br />Timolol<br />&bull; Tramadol (used to treat pain)<br />&bull; Apomorphine (medicine used to treat Parkinson&rsquo;s disease)<br />strong drop in blood pressure and loss of consciousness<br />with simultaneous application of Ondansetron have been<br />reported with Apomorphine.<br />&bull; Medicines that affect the heart (such as Haloperidol or<br />Methadone)</p><p>Cancer medicines (especially Anthracyclines such as<br />Doxorubicin, Daunorubicin or Trastuzumab)<br />&bull; SSRIs (Selective Serotonin Reuptake Inhibitors) used to<br />treat depression and/or anxiety including Fluoxetine,<br />Paroxetine, Sertraline, Fluvoxamine, Citalopram,<br />Escitalopram<br />&bull; SNRIs (Serotonin Noradrenaline Reuptake Inhibitors) used<br />to treat depression and/or anxiety including Venlafaxine,<br />Duloxetine<br />The effect of Ondansetron may be weakened if you are<br />taking Phenytoin, Carbamazepine or Rifampicin. The<br />painkilling effect of Tramadol may be weakened if you are<br />taking Ondansetron.<br />Contact your doctor. It may be necessary to adjust the dose.<br />Ondron with food and drink<br />You may use Ondron independently of food and drink<br />Pregnancy, Breastfeeding and Fertility<br />Pregnancy<br />Because of insufficient experience the use of Ondansetron in<br />pregnancy is not recommended. If you are pregnant, or<br />breastfeeding, think you may be pregnant or are planning to<br />have a baby, ask your doctor or pharmacist for advice before<br />using this medicine.<br />Breastfeeding<br />Ondansetron may pass into mothers&#39; milk. Therefore,<br />mothers receiving Ondron should not breastfeed their baby.<br />Ask your doctor or pharmacist for advice before taking this<br />medicine.<br />Driving and using machines<br />Ondron will not affect your ability to drive or operate<br />machinery.<br />Important information about some of the ingredients in<br />this medicine<br />This medicinal product contains 2.5mmol (or 57.9 mg)<br />Sodium per maximum daily dose of 32mg. To be taken into<br />consideration by patients on a controlled Sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told<br />you. Check with your doctor or pharmacist if you are not<br />sure.<br />Ondron is normally given by a nurse or doctor. The dose you<br />have been prescribed will depend on the treatment you are<br />having.<br />To prevent nausea and vomiting from chemotherapy or<br />radiotherapy in adults<br />On the day of chemotherapy or radiotherapy the<br />recommended adult dose is 8mg given by an injection into<br />your vein or muscle, just before your treatment, and another<br />8mg twelve hours later. After chemotherapy, your medicine<br />will usually be given by mouth as an 8mg Ondansetron tablet<br />or 10ml (8mg) Ondansetron syrup.<br />On the following days<br />&bull; the usual adult intravenous dose does not exceed 8mg tablet<br />or 10ml (8 mg) syrup taken twice a day.<br />&bull; oral dosing can commence twelve hours later and may be<br />continued for up to 5 days.<br />If your chemotherapy or radiotherapy is likely to cause<br />severe nausea and vomiting, you may be given more than the<br />usual dose of Ondron. Your doctor will decide this.<br />To prevent nausea and vomiting from chemotherapy in<br />children aged over 6 months and adolescents<br />The doctor will decide the dose.<br />On the day of chemotherapy<br />&bull; the first dose is given by an injection into the vein, just<br />before your child&rsquo;s treatment. After chemotherapy, your<br />child&rsquo;s medicine will usually be given by mouth; the usual<br />dose is a 4mg.<br />On the following days<br />&bull; 2.5ml (2mg) syrup twice a day for small children and those<br />weighing 10kg or less<br />&bull; one 4mg tablet or 5ml (4mg) syrup twice a day for larger<br />children and those weighing more than 10kg<br />&bull; two 4mg tablets or 10ml (8mg) syrup twice a day for<br />teenagers (or those with a large body surface area)<br />&bull; these doses can be given for up to five days<br />To prevent and treat nausea and vomiting after an<br />operation<br />Adults:<br />&bull; The usual dose for adults is 4mg given by an injection into<br />your vein or an injection into your muscle. For prevention<br />this will be given just before your operation..</p><p>The following information is intended for medical or<br />healthcare professionals only<br />Instructions for use:<br />For intravenous injection or intramuscular injection or<br />intravenous infusion after dilution.<br />Prescribers intending to useOndansetron in the prevention of<br />delayed nausea and vomiting associated with chemotherapy or<br />radiotherapy in adults, adolescents or children should take into<br />consideration current practice and appropriate guidelines.<br />Chemotherapy and radiotherapy induced nausea and<br />vomiting:<br />Adults: The emetogenic potential of cancer treatment varies<br />according to the doses and combinations of chemotherapy<br />and radiotherapy regimens used. The route of administration<br />and dose of Ondansetron should be flexible in the range of<br />8-32mg a day and selected as shown below:<br />Emetogenic chemotherapy and radiotherapy:<br />Ondansetron can be given either by rectal, oral (tablets or<br />syrup), intravenous or intramuscular administration.<br />For most patients receiving emetogenic chemotherapy or<br />radiotherapy, Ondansetron 8mg should be administered as a<br />slow intravenous injection (in not less than 30 seconds) or<br />intramuscular injection, immediately before treatment<br />followed by 8mg orally twelve hourly.<br />To protect against delayed or prolonged emesis after the first<br />24 hours, oral or rectal treatment with Ondansetron should be<br />continued for up to 5 days after a course of treatment.<br />Highly emetogenic chemotherapy: For patients receiving<br />highly emetogenic chemotherapy, e.g. high-dose Cisplatin,<br />Ondansetron can be given either by oral, rectal, intravenous<br />or intramuscular administration. Ondansetron has been<br />shown to be equally effective in the following dose schedules<br />over the first 24 hours of chemotherapy:<br />&bull; A single dose of 8mg by slow intravenous injection (in not<br />less than 30 seconds) or intramuscular injection<br />immediately before chemotherapy.<br />&bull; A dose of 8mg by slow intravenous injection (in not less<br />than 30 seconds) or intramuscular doses of 8mg two to four<br />hours apart, or by a constant infusion of 1mg/hour for up to<br />24 hours.<br />&bull; A maximum initial intravenous dose of 16mg diluted in<br />50-100ml of Saline or other compatible infusion fluid (see<br />Section 6.6 of the SPC) and infused over not less than 15<br />minutes immediately before chemotherapy. The initial dose<br />of Ondansetron may be followed by two additional 8mg<br />intravenous doses (in not less than 30 seconds) or<br />intramuscular doses four hours apart.<br />&bull; A single dose greater than 16mg must not be given due to<br />dose dependent increase of QT-prolongation risk (see<br />Sections 4.4, 4.8 and 5.1 of the SPC).<br />The selection of dose regimen should be determined by the<br />severity of the emetogenic challenge.<br />The efficacy of Ondansetron in highly emetogenic<br />chemotherapy may be enhanced by the addition of a single</p><p>intravenous dose of Dexamethasone Sodium Phosphate,<br />20mg administered prior to chemotherapy.<br />To protect against delayed or prolonged emesis after the first<br />24 hours, oral or rectal treatment with Ondansetron should be<br />continued for up to 5 days after a course of treatment.<br />Paediatric Population:<br />CINV in children aged &ge; 6 months and adolescents<br />The dose for CINV can be calculated based on body surface<br />area (BSA) or weight &ndash; see below:<br />Dosing by BSA:<br />Ondron should be administered immediately before<br />chemotherapy as a single intravenous dose of 5mg/m2.The<br />single intravenous dose must not exceed 8mg. Oral dosing<br />can commence twelve hours later and may be continued for<br />up to 5 days (see SPC for dosing tables). The total dose over<br />24 hours (given as divided doses) must not exceed adult dose<br />of 32mg.<br />Dosing by bodyweight:<br />Weight-based dosing results in higher total daily doses<br />compared to BSA-based dosing. Ondron should be<br />administered immediately before chemotherapy as a single<br />intravenous dose of 0.15mg/kg. The single intravenous dose<br />must not exceed 8mg. Two further intravenous doses may be<br />given in 4-hourly intervals. Oral dosing can commence 12<br />hours later and may be continued for up to 5 days (see SPC<br />for further details).<br />Ondron should be diluted in 5% Dextrose or 0.9% Sodium<br />Chloride or other compatible infusion fluid (see Section 6.6)<br />and infused intravenously over not less than 15 minutes.<br />There are no data from controlled clinical trials on the use of<br />Ondansetron in the prevention of delayed or prolonged<br />CINV.<br />There are no data from controlled clinical trials on the use of<br />Ondansetron for radiotherapy-induced nausea and vomiting<br />in children.<br />Post-operative nausea and vomiting (PONV):<br />Adults: For the prevention of PONV, Ondansetron can be<br />administered orally or by intravenous or intramuscular<br />injection.<br />Ondansetron may be administered as a single dose of 4mg<br />given by intramuscular or slow intravenous injection at<br />induction of anesthesia.<br />For treatment of established PONV a single dose of 4mg<br />given by intramuscular or slow intravenous injection is<br />recommended.<br />Children (aged over 1 month and adolescents)<br />Oral formulation:<br />No studies have been conducted on the use of orally<br />administered ondansetron in the prevention or treatment of<br />post-operative nausea and vomiting; slow i.v. injection is<br />recommended for this purpose</p><p>Children:<br />&bull; For children aged over 1 month and adolescents, the doctor<br />will decide the dose. The maximum dose is 4mg given as a<br />slow injection into the vein. For prevention this will be<br />given just before the operation.<br />Patients with moderate or severe liver problems<br />The total daily dose should not be more than 8mg.<br />If you keep feeling or being sick<br />Ondron should start to work soon after having the injection.<br />If you continue to be sick or feel sick, tell your doctor or<br />nurse.<br />If you have more Ondron than you should<br />Your doctor or nurse will give you or your child Ondron so it<br />is unlikely that you or your child will receive too much. If<br />you think you or your child have been given too much or<br />have missed a dose, tell your doctor or nurse.<br />If you have any further questions on the use of this medicine,<br />ask your doctor, pharmacist or nurse..</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects,<br />although not everybody gets them.<br />SERIOUS SIDE EFFECTS<br />Allergic Reactions<br />If you have an allergic reaction, tell your doctor or a member<br />of the medical staff straightaway. The signs may include:<br />&bull; sudden wheezing and chest pain or chest tightness<br />&bull; swelling of your eyelids, face, lips, mouth or tongue<br />&bull; skin rash &ndash; red spots or lumps under your skin (hives)<br />anywhere on your body<br />&bull; collapse<br />Less serious side-effects<br />Very common (may affect more than 1 in 10 people)<br />&bull; headache<br />Common (may affect up to 1 in 10 people)<br />&bull; sensations of flushing or warmth<br />&bull; constipation<br />&bull; changes to liver function test results (if you have Ondron<br />with a medicine called Cisplatin, otherwise this side effect<br />is uncommon)<br />&bull; irritation and redness at the site of injection<br />Uncommon (may affect up to 1 in 100 people)<br />&bull; seizures (fits or convulsions)<br />&bull; unusual body movements or shaking<br />&bull; uneven heart beat<br />&bull; chest pain<br />&bull; low blood pressure, which can make you feel faint or dizzy<br />&bull; hiccups<br />Rare (may affect up to 1 in 1,000 people)<br />&bull; feeling dizzy or light headed<br />&bull; blurred vision<br />&bull; disturbance in heart rhythm (sometimes causing a sudden<br />loss of consciousness)<br />Very rare (may affect up to 1 in 10,000 people)<br />&bull; poor vision or temporary loss of eyesight, which usually<br />comes back within 20 minutes<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist.<br />This includes any possible side effects not listed in this<br />leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of sight and reach of children.<br />Do not use this medicine after the expiry date which is stated<br />on the pack. The expiry date refers to the last day of that<br />month.<br />Do not store above 30&deg;C. Store in the original pack in order<br />to protect from light.<br />Do not use this medicine if you notice container is damaged.<br />Do not use this medicine if you notice that the solution is not<br />clear or contains particles.<br />After first opening the medicinal product should be used<br />immediately.<br />When Ondron is diluted in intravenous fluids, it must be<br />stored at 2-8&deg;C for not more than 24 hours<br />From a microbiological point of view, the product should be<br />used immediately. If not used immediately, in-use storage<br />times and conditions prior to use are the responsibility of the<br />user and would normally not be longer than 24 hours at 2 to<br />8&deg;C, unless dilution has taken place in controlled and<br />validated aseptic conditions.<br />Do not throw away any medicines via wastewater or<br />household waste. Ask your pharmacist how to throw away<br />medicines you no longer use. These measures will help<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Ondron contains<br />The active substance is Ondansetron.<br />Each ampoule of 2ml contains 4mg of Ondansetron (as<br />Ondansetron hydrochloride dihydrate).<br />Each ampoule of 4ml contains 8mg of Ondansetron (as<br />Ondansetron hydrochloride dihydrate).<br />The other ingredients are citric acid monohydrate, sodium<br />citrate, sodium chloride and water for injection. Sodium<br />hydroxide and/or hydrochloric acid may have been used to<br />adjust pH.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ondron is a colourless, clear solution filled in glass ampoules
containing 2ml or 4ml of solution for
injection or infusion.
Each pack contains 5 or 10 ampoules.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder (MAH):<br />Accord Healthcare Limited<br />Sage House, 319 Pinner Road, North Harrow,<br />Middlesex HA1 4HF, United Kingdom<br />Tel: +44 208 863 1427<br />Fax: +44 208 863 1426<br />E-mail: mena-info@accord-healthcare.com<br />Manufactured for Accord Healthcare Limited by<br />Intas Pharmaceuticals Limited, Ahmedabad, Gujarat state,<br />India.<br />For any information about this medicinal product, please<br />contact the local representative of the MAH:<br />Accord Healthcare KSA Scientific Office<br />PO Box 56980, Riyadh 11564, Saudi Arabia<br />Tel: +966 50 0200922<br />E-mail: mena-pv@accord-healthcare.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 11/2018, version number
SA-03
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>NA Hospital use</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital use</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital use</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital use</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital use</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital use</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital use</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital use</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            NA Hospital use
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ondron 2mg/ml Solution for Injection or Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml of solution for injection or infusion contains 2mg Ondansetron (as Ondansetron
hydrochloride dihydrate)
Each ampoule with 2ml contains 4mg Ondansetron (as Ondansetron hydrochloride dihydrate).
Each ampoule with 4ml contains 8mg Ondansetron (as Ondansetron hydrochloride dihydrate).
Excipient with known effect: 1ml solution for injection or infusion contains 3.62mg of Sodium as
Sodium Citrate, Sodium Chloride and Sodium Hydroxide.
For the full list of excipients, see Section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for Injection or Infusion
Clear colourless solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults:<br />Management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.<br />Prevention and treatment of post‐operative nausea and vomiting (PONV).<br />Paediatric Population:<br />Management of chemotherapy‐induced nausea and vomiting in children aged &ge;6 months.<br />Prevention and treatment of post‐operative nausea and vomiting in children aged &ge; 1 month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Chemotherapy and radiotherapy induced nausea and vomiting:<br />Adults: The emetogenic potential of cancer treatment varies according to the doses and<br />combinations of chemotherapy and radiotherapy regimens used. The route of administration and<br />dose of Ondansetron should be flexible in the range of 8‐32mg a day and selected as shown below.</p><p>Emetogenic chemotherapy and radiotherapy:<br />Ondansetron can be given either by rectal, oral (tablets or syrup), intravenous or intramuscular<br />administration.<br />For most patients receiving emetogenic chemotherapy or radiotherapy, Ondansetron 8mg should be<br />administered as a slow intravenous injection (in not less than 30 seconds) or intramuscular injection,<br />immediately before treatment followed by 8mg orally twelve hourly.<br />To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with<br />Ondansetron should be continued for up to 5 days after a course of treatment.<br />Highly emetogenic chemotherapy: For patients receiving highly emetogenic chemotherapy, e.g. highdose<br />Cisplatin, Ondansetron can be given either by oral, rectal, intravenous or intramuscular<br />administration. Ondansetron has been shown to be equally effective in the following dose schedules<br />over the first 24 hours of chemotherapy:<br />&middot; A single dose of 8mg by slow intravenous injection (in not less than 30 seconds) or intramuscular<br />injection immediately before chemotherapy.<br />&middot; A dose of 8mg by slow intravenous injection (in not less than 30 seconds) or intramuscular doses<br />of 8mg two to four hours apart, or by a constant infusion of 1mg/hour for up to 24 hours.<br />&middot; A maximum initial intravenous dose of 16mg diluted in 50‐100ml of Saline or other compatible<br />infusion fluid (see Section 6.6) and infused over not less than 15 minutes immediately before<br />chemotherapy. The initial dose of Ondansetron may be followed by two additional 8mg<br />intravenous doses (in not less than 30 seconds) or intramuscular doses four hours apart.<br />&middot; A single dose greater than 16mg must not be given due to dose dependent increase of QTprolongation<br />risk (see Sections 4.4, 4.8 and 5.1)<br />The selection of dose regimen should be determined by the severity of the emetogenic challenge.<br />The efficacy of Ondansetron in highly emetogenic chemotherapy may be enhanced by the addition<br />of a single intravenous dose of Dexamethasone Sodium Phosphate, 20mg administered prior to<br />chemotherapy.<br />To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with<br />Ondansetron should be continued for up to 5 days after a course of treatment.<br />Paediatric Population:<br />CINV in children aged &ge;6 months and adolescents:<br />The dose of CINV can be calculated based on body surface area (BSA) or weight &ndash; see below. In<br />paediatric clinical studies, Ondansetron was given by IV infusion diluted in 25 to 50ml of Saline or<br />other compatible infusion fluid and infused over not less than 15 minutes.<br />Weight‐based dosing results in higher total daily doses compared to BSA‐based dosing &ndash; see Sections<br />4.4 and 5.1<br />Ondansetron hydrochloride should be diluted in 5% Dextrose or 0.9% Sodium Chloride or other<br />compatible infusion fluid (see Section 6.6) and infused intravenously over not less than 15 minutes.</p><p>There are no data from controlled clinical trials on the use of Ondansetron Injection in the<br />prevention of delayed or prolonged CINV. There are no data from controlled clinical trials on the use<br />of Ondansetron Injection for radiotherapy‐induced nausea and vomiting in children.<br />Dosing by BSA:<br />Ondansetron should be administered immediately before chemotherapy as a single intravenous<br />dose of 5mg/m2. The single intravenous dose must not exceed 8mg.<br />Oral dosing can commence twelve hours later and may be continued for up to 5 days. (Table 1).<br />The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32mg.<br />Table 1: BSA‐based dosing for Chemotherapy ‐ Children aged &ge;6 months and adolescents</p><table border="1" cellspacing="1" cellpadding="0" style="width:500px"><tbody><tr><td><p>BSA</p></td><td><p>Day 1a,b</p></td><td><p>Days 2‐6(b)</p></td></tr><tr><td><p>&lt; 0.6m2</p></td><td><p>5mg/m2 IV plus 2mg syrup after 12 hours</p></td><td><p>2mg syrup every 12 hours</p></td></tr><tr><td><p>&ge;0.6m2 to &le; 1.2m2</p></td><td><p>5mg/m2 IV plus 4mg syrup after 12 hours</p></td><td><p>4mg syrup or tablet every 12<br />hours</p></td></tr><tr><td><p>&gt; 1.2m2</p></td><td><p>5mg/m2 or 8mg syrup or tablet after 12<br />hours</p></td><td><p>8mg syrup or tablet every 12<br />hours</p></td></tr></tbody></table><p>a The intravenous dose must not exceed 8mg.<br />b The total daily dose over 24 hours (given as divided doses) must not exceed adult dose of 32mg.<br />Dosing by bodyweight:<br />Weight‐based dosing results in higher total daily doses compared to BSA‐based dosing (see Sections<br />4.4 and 5.1).<br />Ondansetron should be administered immediately before chemotherapy as a single intravenous<br />dose of 0.15mg/Kg. The single intravenous dose must not exceed 8mg.<br />Two further intravenous doses may be given in 4‐hourly intervals.<br />Oral dosing can commence 12 hours later and may be continued for up to 5 days (Table 2).<br />The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32mg.<br />Table 2: Weight‐based dosing for Chemotherapy ‐ Children aged &ge;6 months and adolescents</p><table border="1" cellspacing="1" cellpadding="0" style="width:500px"><tbody><tr><td><p>Weight</p></td><td><p>Day1(a,b)</p></td><td><p>Days 2‐6(b)</p></td></tr><tr><td><p>&le;10 kg</p></td><td><p>Up to 3 doses of 0.15mg/kg IV every 4 hrs</p></td><td><p>2mg syrup every 12 hrs</p></td></tr><tr><td><p>&gt; 10 kg</p></td><td><p>Up to 3 doses of 0.15mg/kg IV every 4 hrs</p></td><td><p>4mg syrup or tablet every 12<br />hrs</p></td></tr></tbody></table><p>a The intravenous dose must not exceed 8mg.<br />b The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32mg.<br />Elderly:<br />In patients 65 to 74 years of age, the dose schedule for adults can be followed. All intravenous doses<br />should be diluted in 50‐100ml of Saline or other compatible infusion fluid (see Section 6.6) and<br />infused over 15 minutes.</p><p>In patients 75 years of age or older, the initial intravenous dose of Ondansetron should not exceed<br />8mg. All intravenous doses should be diluted in 50‐100ml of Saline or other compatible infusion fluid<br />(see Section 6.6) and infused over 15 minutes.<br />The initial dose of 8mg may be followed by two further intravenous doses of 8mg, infused over 15<br />minutes and given no less than four hours apart (see Section 5.2).<br />Patients with renal impairment:<br />No alteration of daily dosage or frequency of dosing, or route of administration is required.<br />Patients with Hepatic impairment:<br />Clearance of Ondansetron is significantly reduced and serum half‐life significantly prolonged in<br />subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose<br />of 8mg should not be exceeded and therefore parenteral or oral administration is recommended.<br />Patients with poor Sparteine/Debrisoquine metabolism:<br />The elimination half‐life of Ondansetron is not altered in subjects classified as poor metabolizers of<br />Sparteine and Debrisoquine. Consequently, in such patients repeat dosing will give drug exposure<br />levels no different from those of the general population. No alteration of daily dosage or frequency<br />of dosing is required.<br />Post‐operative nausea and vomiting (PONV):<br />Adults:<br />For the prevention of PONV: Ondansetron can be administered orally or by intravenous or<br />intramuscular injection.<br />Ondansetron may be administered as a single dose of 4mg given by intramuscular or slow<br />intravenous injection at induction of anesthesia.<br />For treatment of established PONV: A single dose of 4mg given by intramuscular or slow intravenous<br />injection is recommended.<br />Paediatric population:<br />PONV in children aged &ge; 1 month and adolescents.<br />For prevention of PONV in paediatric patients having surgery performed under general anesthesia, a<br />single dose of Ondansetron may be administered by slow intravenous injection (not less than 30<br />seconds) at a dose 0.1mg/Kg up to a maximum of 4mg either prior to, at or after induction of<br />anesthesia.<br />For the treatment of PONV after surgery in paediatric patients having surgery performed under<br />general anesthesia, a single dose of Ondansetron may be administered by slow intravenous injection<br />(not less than 30 seconds) at a dose of 0.1mg/kg up to a maximum of 4mg.<br />There are no data on the use of Ondansetron in the treatment of PONV children below 2 years of<br />age.<br />Elderly:<br />There is limited experience in the use of Ondansetron in the prevention and treatment of PONV in<br />the elderly however Ondansetron is well tolerated in patients over 65 years receiving chemotherapy.<br />Patients with renal impairment:<br />No alteration of daily dosage or frequency of dosing, or route of administration is required.</p><p>Patients with hepatic impairment:<br />Clearance of Ondansetron is significantly reduced and serum half‐life significantly prolonged in<br />subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose<br />of 8mg should not be exceeded and therefore parental or oral administration is recommended.<br />Patients with poor Sparteine/Debrisoquine metabolism:<br />The elimination half‐life of Ondansetron is not altered in subjects classified as poor metabolizers of<br />Sparteine and Debrisoquine. Consequently, in such patients repeat dosing will give drug exposure<br />levels no different from those of the general population. No alteration of daily dosage or frequency<br />of dosing are required.<br />Method of administration<br />For intravenous injection or intramuscular injection or intravenous infusion after dilution.<br />For instructions on dilution of the product before administration, see Section 6.6<br />Prescribers intending to use Ondansetron in the prevention of delayed nausea and vomiting<br />associated with chemotherapy or radiotherapy in adults, adolescents or children should take into<br />consideration current practice and appropriate guidelines</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Concomitant use with Apomorphine (see Section 4.5).
 Hypersensitivity to any component of the preparation.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to<br />other selective 5HT3 receptor antagonists.<br />Respiratory events should be treated symptomatically and clinicians should pay particular attention<br />to them as precursors of hypersensitive reactions.<br />Ondansetron prolongs the QT interval in a dose‐dependent manner (see Section 5.1). In addition,<br />post‐marketing cases of Torsade de Pointes have been reported in patients using Ondansetron.<br />Avoid Ondansetron in patients with congenital long QT syndrome. Ondansetron should be<br />administered with caution to patients who have or may develop prolongation of QTc, including<br />patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias patients taking<br />other medicinal products that lead to QT prolongation or electrolyte abnormalities.<br />Hypokalemia and hypomagnesemia should be corrected prior to Ondansetron administration.<br />There have been post‐marketing reports describing patients with Serotonin Syndrome (including<br />altered mental status, autonomic instability and neuromuscular abnormalities) following the<br />concomitant use of Ondansetron and other serotonergic drugs (including Selective Serotonin<br />Reuptake Inhibitors (SSRI) and Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)). If concomitant<br />treatment with Ondansetron and other serotonergic drugs is clinically warranted, appropriate<br />observation of the patient is advised.</p><p>As Ondansetron is known to increase large bowel transit time, patients with signs of subacute<br />intestinal obstruction should be monitored following administration<br />In patients with adenotonsillar surgery prevention of nausea and vomiting with Ondansetron may<br />mask occult bleeding. Therefore, such patients should be followed carefully after Ondansetron.<br />Ondansetron Accord contains 2.5mmol (or 57.9mg) sodium per maximum daily dose of 32mg. To be<br />taken into consideration by patients on a controlled Sodium Diet.<br />Paediatric Population:<br />Paediatric patients receiving Ondansetron with hepatotoxic chemotherapeutic agents should be<br />monitored closely for impaired hepatic function.<br />CINV:<br />When calculating the dose on an mg/kg basis and administering three doses at 4‐hour intervals, the<br />total daily dose will be higher than if one single dose of 5mg/m2 followed by an oral dose is given.<br />The comparative efficacy of these two different dosing regimens has not been investigated in clinical<br />trials. Cross trial comparison indicates similar efficacy for both regimens (see Section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence that Ondansetron either induces or inhibits the metabolism of other drugs<br />commonly co‐administered with it. Specific studies have shown that there are no pharmacokinetic<br />interactions when Ondansetron is administered with Alcohol, Temazepan.<br />Ondansetron is metabolized by multiple hepatic cytochrome P‐450 enzymes: CYP3A4, CYP2D6 and<br />CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolizing Ondansetron, enzyme<br />inhibition or reduced activity of one enzyme (e.g. CYP2D6 genetic deficiency) is normally<br />compensated by other enzymes and should result in little or no significant change in overall<br />Ondansetron clearance or dose requirement.<br />Caution should be exercised when Ondansetron is coadministered with drugs that prolong the QT<br />interval and/or cause electrolyte abnormalities (See Section 4.4).<br />Use of Ondansetron with QT prolonging drugs may result in additional QT prolongation.<br />Concomitant use of Ondansetron with cardiotoxic drugs (e.g. Anthracyclines (such as Doxorubicin,<br />Daunorubicin or Trastuzumab), Antibiotics (such as Erythromycin), Antifungals (such as<br />Ketoconazole), Antiarrhythmics (such as Amiodarone) and Beta Blockers (such as Atenolol or<br />Timolol) may increase the risk of arrhythmias (See Section 4.4).<br />Serotonergic Drugs (e.g. SSRIs and SNRIs):<br />There have been post‐marketing reports describing patients with Serotonin Syndrome (including<br />altered mental status, autonomic instability and neuromuscular abnormalities) following the<br />concomitant use of Ondansetron and other serotonergic drugs (including SSRIs and SNRIs) (See<br />Section 4.4)<br />Apomorphine: Based on reports of profound hypotension and loss of consciousness when<br />Ondansetron was administered with Apomorphine Hydrochloride, concomitant use with<br />Apomorphine is contraindicated.</p><p>Phenytoin, Carbamazepine and Rifampicin:<br />In patients treated with potent inducers of CYP3A4 (i.e. Phenytoin, Carbamazepine, and Rifampicin),<br />the oral clearance of Ondansetron was increased and Ondansetron blood concentrations were<br />decreased.<br />Tramadol:<br />Data from small studies indicate that Ondansetron may reduce the analgesic effect of Tramadol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />The safety of Ondansetron for use in human pregnancy has not been established. Evaluation of<br />experimental animal studies does not indicate direct or indirect harmful effects with respect to the<br />development of the embryo, or foetus, the course of gestation and pre‐ and post‐natal<br />development. However as animal studies are not always predictive of human response the use of<br />Ondansetron in pregnancy is not recommended.<br />Breastfeeding<br />Tests have shown that Ondansetron passes into the milk of lactating animals. It is therefore<br />recommended that mothers receiving Ondansetron should not breastfeed their babies.<br />Fertility<br />There is no information on the effects of Ondansetron on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In psychomotor testing, Ondansetron does not impair performance nor cause sedation. No<br />detrimental effects on such activities are predicted from the pharmacology of Ondansetron.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.8 Undesirable effects<br />Adverse events are listed below by system organ class and frequency. Frequencies are defined as:<br />Very common (&ge;1/10)<br />Common ( 1/100 and &lt;1/10)<br />Uncommon ( 1/1000 to &lt;1/100)<br />Rare ( 1/10,000 and &lt;1/1000)<br />&amp;<br />Very rare (&lt;1/10,000)<br />Very common, common and uncommon events were generally determined from clinical trial data.<br />The incidence in placebo was taken into account. Rare and very rare events were generally<br />determined from post‐marketing spontaneous data.<br />The following frequencies are estimated at the standard recommended doses of Ondansetron. The<br />adverse event profiles in children and adolescents were comparable to that seen in adults.<br />Immune system disorders<br />Rare: Immediate hypersensitivity reactions sometimes severe, including anaphylaxis.</p><p>Nervous system disorders<br />Very common: Headache.<br />Uncommon: Seizures, movement disorders (including extrapyramidal reactions such as dystonic<br />reactions, oculogyric crisis and dyskinesia)(1).<br />Rare: Dizziness during rapid IV administration.<br />Eye disorders<br />Rare: Transient visual disturbances (eg. blurred vision) predominantly during IV<br />administration.<br />Very rare: Transient blindness predominantly during intravenous administration(2).<br />Cardiac disorders<br />Uncommon: Arrhythmias, chest pain with or without ST segment depression, bradycardia.<br />Rare: QTc prolongation (including Torsade de Pointes).<br />Vascular disorders<br />Common: Sensation of warmth or flushing.<br />Uncommon: Hypotension.<br />Respiratory, thoracic and mediastinal disorders<br />Uncommon: Hiccups.<br />Gastrointestinal disorders<br />Common: Constipation.<br />Hepatobiliary disorders<br />Uncommon: Asymptomatic increases in liver function tests (3).<br />General disorders and administration site conditions<br />Common: local IV injection site reactions.<br />1. Observed without definitive evidence of persistent clinical sequelae.<br />2. The majority of the blindness cases reported resolved within 20 minutes. Most patients had<br />received chemotherapeutic agents, which included Cisplatin. Some cases of transient<br />blindness were reported as cortical in origin.<br />3. These events were observed commonly in patients receiving chemotherapy with Cisplatin.<br />Reporting of suspected adverse reactions<br />To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966‐11‐205‐7662<br />Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.<br />Toll free phone: 8002490000<br />E‐mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms and Signs<br />There is limited experience of Ondansetron overdose. In the majority of cases, symptoms were<br />similar to those already reported in patients receiving recommended doses (see Section 4.8).<br />Manifestations that have been reported include visual disturbances, severe constipation,<br />hypotension and a vasovagal episode with transient second degree AV block.<br />Ondansetron prolongs the QT interval in a dose‐dependent fashion. ECG monitoring is<br />recommended in cases of overdose.<br />Treatment<br />There is no specific antidote for Ondansetron, therefore in all cases of suspected overdose,<br />symptomatic and supportive therapy should be given as appropriate.<br />The use of Ipecacuanha to treat overdose with Ondansetron is not recommended, as patients are<br />unlikely to respond due to the anti‐emetic action of Ondansetron itself.<br />Paediatric population<br />Paediatric cases consistent with Serotonin Syndrome have been reported after inadvertent oral<br />overdoses of Ondansetron (exceeded estimated ingestion of 4mg/kg) in infants and children aged 12<br />months to 2 years.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code:‐ A04 Antiemetics and Antinauseants<br />ATC group:‐ A04AAO 1 Serotonin (5HT3) antagonist<br />Mechanism of Action<br />Ondansetron is a potent, highly selective 5HT3 receptor‐antagonist.<br />Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic<br />agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex<br />by activating vagal afferents via 5HT3 receptors. Ondansetron blocks the initiation of this reflex.<br />Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the<br />floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus,<br />the effect of Ondansetron in the management of the nausea and vomiting induced by cytotoxic<br />chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons<br />located both in the peripheral and central nervous system.<br />The mechanisms of action in post‐operative nausea and vomiting are not known but there may be<br />common pathways with cytotoxic induced nausea and vomiting.<br />Ondansetron does not alter plasma Prolactin concentrations.<br />The role of Ondansetron in Opiate‐induced emesis is not yet established.</p><p>QT Prolongation<br />The effect of Ondansetron on the QTc interval was evaluated in a double blind, randomized, placebo<br />and positive (Moxifloxacin) controlled, crossover study in 58 healthy adult men and women.<br />Ondansetron doses included 8mg and 32mg infused intravenously over 15 minutes. At the highest<br />tested dose of 32mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo<br />after baseline‐correction was 19.6 (21.5) msec. At the lower tested dose of 8mg, the maximum mean<br />(upper limit of 90% CI) difference in QTcF from placebo after baseline‐correction was 5.8 (7.8) msec.<br />In this study, there were no QTcF measurements greater than 480 msec and no QTcF prolongation<br />was greater than 60 msec. No significant changes were seen in the measured electrocardiographic<br />PR or QRS intervals.<br />Paediatric Population:<br />CINV<br />The efficacy of Ondansetron in the control of emesis and nausea induced by cancer chemotherapy<br />was assessed in a double‐blind randomized trial in 415 patients aged 1 to 18 years (S3AB3006). On<br />the days of chemotherapy, patients received either Ondansetron 5mg/m2 intravenous and<br />Ondansetron 4mg orally after 8 to 12 hours or Ondansetron 0.45mg/Kg intravenous and placebo<br />after 8 to 12 hours. Post‐chemotherapy both groups received 4mg Ondansetron syrup twice daily for<br />3 days. Complete control of emesis on worst day of chemotherapy was 49% (5mg/m2 intravenous<br />and Ondansetron 4mg orally) and 41% (0.45mg/Kg intravenous and placebo orally). Postchemotherapy<br />both groups received 4mg Ondansetron syrup twice daily for 3 days. There was no<br />difference in the overall incidence or nature of adverse events between the two treatment groups.<br />A double‐blind randomised placebo‐controlled trial(S3AB4003) in 438 patients aged 1 to 17 years<br />demonstrated complete control of emesis on worst day of chemotherapy in:<br />&middot; 73% of patients when Ondansetron was administered intravenously at a dose of 5mg/m2<br />intravenous together with 2‐4 mg Dexamethasone orally.<br />&middot; 71% of the patients when Ondansetron was administered as a syrup at a dose of 8mg<br />together with 2 to 4 mg Dexamethasone orally on the days of chemotherapy.</p><p>Post‐chemotherapy both groups received 4mg Ondansetron syrup twice daily for 2 days. There was<br />no difference in the overall incidence or nature of adverse events between the two treatment<br />groups.<br />The efficacy of Ondansetron in 75 children aged 6 to 48 months was investigated in an open‐label,<br />non‐comparative, single‐arm study (S3A40320). All children receive three 0.15mg/Kg doses of<br />intravenous Ondansetron, administered at 30 minutes before the start of chemotherapy and then at<br />4 and 8 hours after the first dose. Complete control of emesis was achieved in 56% of patients.<br />Another open‐label, non‐comparative, single‐arm study (S3A239) investigated the efficacy of one<br />intravenous dose of 0.15mg/Kg Ondansetron followed by two Ondansetron doses of 4mg for<br />children aged &lt; 12 years and 8mg for children aged &ge; 12 years (total no. of children n = 28).<br />Complete control of emesis was achieved in 42% of patients.<br />PONV<br />The efficacy of a single dose of Ondansetron in the prevention of post‐operative nausea and<br />vomiting was investigated in a randomized, double‐blind, placebo‐controlled study in 670 children<br />aged 1 to 24 months (post‐conceptual age &ge; 44 weeks, weight &ge; 3 Kg). Included subjects were<br />scheduled to undergo effective surgery under general anesthesia and had an ASA status &le; III. A single</p><p>dose of Ondansetron 0.1mg/Kg was administered within five minutes following induction of<br />anesthesia. The proportion of subjects who experienced at least one emetic episode during the 24‐<br />hour assessment period (ITT) was greater for patients on placebo than those receiving Ondansetron<br />(28% vs. 11%, p&lt;0.0001).<br />Four double‐blind, placebo‐controlled studies have been performed in 1469 male and female<br />patients (2 to 12 years of age) undergoing general anesthesia. Patients were randomized to either<br />single intravenous doses of Ondansetron (0.1mg/kg for paediatric patients weighing 40 kg or less,<br />4mg for paediatric patients weighing more than 40kg; number of patients = 735)) or placebo<br />(number of patients = 734). Study drug was administered over at least 30 seconds, immediately prior<br />to or following anesthesia induction. Ondansetron was significantly more effective than placebo in<br />preventing nausea and vomiting. The results of these studies are summarized in Table 3.<br />Table 3 Prevention and treatment of PONV in Paediatric Patients &ndash; Treatment response over 24<br />hours</p><table border="1" cellspacing="1" cellpadding="0" style="width:500px"><tbody><tr><td><p>Study</p></td><td><p>Endpoint</p></td><td><p>Ondansetron %</p></td><td><p>Placebo %</p></td><td><p>p value</p></td></tr><tr><td><p>S3A380</p></td><td><p>CR</p></td><td><p>68</p></td><td><p>39</p></td><td><p>0.001</p></td></tr><tr><td><p>S3GT09</p></td><td><p>CR</p></td><td><p>61</p></td><td><p>35</p></td><td><p>0.001</p></td></tr><tr><td><p>S3A381</p></td><td><p>CR</p></td><td><p>53</p></td><td><p>17</p></td><td><p>0.001</p></td></tr><tr><td><p>S3GT11</p></td><td><p>no nausea</p></td><td><p>64</p></td><td><p>51</p></td><td><p>0.004</p></td></tr><tr><td><p>S3GT11</p></td><td><p>no emesis</p></td><td><p>60</p></td><td><p>47</p></td><td><p>0.004</p></td></tr></tbody></table><p>CR = no emetic episodes, rescue or withdrawal</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Following oral administration, Ondansetron is passively and completely absorbed from the<br />gastrointestinal tract and undergoes first pass metabolism. Peak plasma concentrations of about<br />30ng/ml are attained approximately 1.5 hours after an 8mg dose. For doses above 8 mg, the<br />increase in Ondansetron systemic exposure with dose is greater than proportional; this may reflect<br />some reduction in first pass metabolism at higher oral doses. Bioavailability, following oral<br />administration, is slightly enhanced by the presence of food but unaffected by Antacids.<br />Following administration of ondansetron suppository, plasma ondansetron concentrations become<br />detectable between 15 and 60 minutes after dosing. Concentrations rise in an especially linear<br />fashion, until peak concentrations of 20‐30ng/ml are attained, typically 6 hours after dosing. Plasma<br />concentrations then fall, but at a slower rate than observed following oral dosing due to continued<br />absorption of Ondansetron.<br />Studies in healthy elderly volunteers have shown slight, but clinically insignificant, age‐related<br />increases in both oral bioavailability (65%) and half‐life (five hours) of ondansetron.<br />A 4mg intravenous infusion of Ondansetron given over 5 minutes results in peak plasma<br />concentrations of about 65ng/ml. Following intramuscular administration of Ondansetron, peak<br />plasma concentrations of about 25ng/ml are attained within 10 minutes of injection.<br />Distribution<br />The disposition of Ondansetron following oral, intramuscular (IM) and intravenous (IV) dosing is<br />similar with a terminal half‐life of about 3 hours and steady state volume of distribution of about 140<br />L. Equivalent systemic exposure is achieved after intramuscular and intravenous administration of<br />Ondansetron.</p><p>Ondansetron is not highly protein bound (70‐76%).<br />The absolute bioavailability of Ondansetron from the suppository is approximately 60% and is not<br />affected by gender.<br />Biotransformation<br />Ondansetron is cleared from the systemic circulation predominantly by hepatic metabolism through<br />multiple enzymatic pathways. The absence of the enzyme CYP2D6 (the Debrisoquine Polymorphism)<br />has no effect on Ondansetron&#39;s pharmacokinetics.<br />Elimination<br />Less than 5% of the absorbed dose is excreted unchanged in the urine. Terminal half‐life is about 3<br />hours.<br />The pharmacokinetic properties of Ondansetron are unchanged on repeat dosing.<br />The half‐life of the elimination phase following suppository administration is determined by the rate<br />of Ondansetron absorption, not systemic clearance and is approximately 6 hours. Females show a<br />small, clinically insignificant, increase in half‐life in comparison with males.<br />Special Patient Populations<br />Gender<br />Gender differences were shown in the disposition of Ondansetron, with females having a greater<br />rate and extent of absorption following an oral dose and reduced systemic clearance and volume of<br />distribution (adjusted for weight).<br />Children and Adolescents (aged 1 month to 17 years)<br />In paediatric patients aged 1 to 4 months (n=19) undergoing surgery, weight normalized clearance<br />was approximately 30% slower than in patients aged 5 to 24 months (n=22) but comparable to the<br />patients aged 3 to 12 years. The half‐life in the patient population aged 1 to 4 month was reported<br />to average 6.7 hours compared to 2.9 hours for patients in the 5 to 24 month and 3 to 12 year age<br />range. The differences in pharmacokinetic parameters in the 1 to 4 month patient population can<br />be explained in part by the higher percentage of total body water in neonates and infants and a<br />higher volume of distribution for water soluble drugs like Ondansetron.<br />In paediatric patients aged 3 to 12 years undergoing elective surgery with general anesthesia, the<br />absolute values for both the clearance and volume of distribution of Ondansetron were reduced in<br />comparison to values with adult patients. Both parameters increased in a linear fashion with weight<br />and by 12 years of age, the values were approaching those of young adults. When clearance and<br />volume of distribution values were normalized by body weight, the values for these parameters<br />were similar between the different age group populations. Use of weight‐based dosing compensates<br />for age‐related changes and is effective in normalizing systemic exposure in paediatric patients.<br />Population pharmacokinetic analysis was performed on 428 subjects (cancer patients, surgery<br />patients and healthy volunteers) aged 1 month to 44 years following intravenous administration of<br />Ondansetron. Based on this analysis, systemic exposure (AUC) of Ondansetron following oral or IV<br />dosing in children and adolescents was comparable to adults, with the exception of infants aged 1 to<br />4 months. Volume was related to age and was lower in adults than in infants and children. Clearance<br />was related to weight but not to age with the exception of infants aged 1 to 4 months. It is difficult<br />to conclude whether there was an additional reduction in clearance related to age in infants 1 to 4&nbsp;months or simply inherent variability due to the low number of subjects studied in this age group.<br />Since patients less than 6 months of age will only receive a single dose in PONV a decreased<br />clearance is not likely to be clinically relevant.<br />Elderly<br />Early Phase I studies in healthy elderly volunteers have showed a slight age‐related decrease in<br />clearance, and an increase in half‐life of Ondansetron. However, wide inter‐subject variability<br />resulted in considerable overlap in pharmacokinetic parameters between young (&lt; 65 years of age)<br />and elderly subjects (&ge; 65 years of age) and there were no overall differences in safety or efficacy<br />observed between young and elderly cancer patients enrolled in CINV clinical trials to support a<br />different dosing recommendation for the elderly.<br />Based on more recent Ondansetron plasma concentrations and exposure‐response modelling, a<br />greater effect on QTcF is predicted in patients &ge; 75 years of age compared to young adults. Specific<br />dosing information is provided for patients over 65 years of age and over 75 years of age for IV<br />dosing (see Section 4.2).<br />Renal impairment<br />In patients with renal impairment (Creatinine clearance 15‐60ml/min), both systemic clearance and<br />volume of distribution are reduced following IV administration of Ondansetron, resulting in a slight,<br />but clinically insignificant, increase in elimination half‐life (5.4h). A study in patients with severe<br />renal impairment who required regular haemodialysis (studied between dialyses) showed<br />Ondansetron&#39;s pharmacokinetics to be essentially unchanged following intravenous administration.<br />Hepatic impairment<br />Following oral, intravenous or intramuscular dosing in patients with severe hepatic impairment,<br />Ondansetron&#39;s systemic clearance is markedly reduced with prolonged elimination half‐lives (15‐32<br />hours) and an oral bioavailability approaching 100% due to reduced pre‐systemic metabolism. The<br />pharmacokinetics of Ondansetron following</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data revealed no special hazard for humans based on conventional studies of safety<br />pharmacology, repeated‐dose toxicity, genotoxicity and carcinogenic potential.<br />Ondansetron and its metabolites accumulate in the milk of rats at a milk:plasma ratio of 5.2:1.<br />A study in cloned human cardiac ion channels has shown Ondansetron has the potential to affect<br />cardiac repolarization via blockade of HERG potassium channels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1 List of excipients<br />Citric acid monohydrate<br />Sodium citrate<br />Sodium chloride<br />Sodium hydroxide (for pH adjustment)<br />Hydrochloric acid, concentrated (for pH adjustment)<br />Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in<br />Section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months (unopened). 24 hours (dilutions stored 2 ‐ 8°C).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep this medicine out of sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the pack. The expiry date refers to<br />the last day of that month.<br />Do not store above 30&deg;C. Store in the original pack in order to protect from light.<br />Do not use this medicine if container is damaged.<br />Do not use this medicine if you notice that the solution is not clear or contains particles.<br />For storage conditions of the diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ondron 2mg/ml solution for injection or infusion is filled in Type I glass ampoule.<br />Each pack contains 5 or 10 ampoules.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The solution must not be sterilized in an autoclave.<br />Ondron should only be admixed with those infusion solutions which are recommended:<br /> Sodium Chloride Intravenous Infusion BP 0.9% w/v<br /> Glucose Intravenous Infusion BP 5% w/v<br /> Mannitol Intravenous Infusion BP 10% w/v<br /> Ringers Intravenous Infusion<br /> Potassium Chloride 0.3% w/v and Sodium Chloride 0.9% w/v Intravenous Infusion BP<br /> Potassium Chloride 0.3% w/v and Glucose 5% w/v Intravenous Infusion BP<br />The stability of Ondansetron Injection after dilution with the recommended infusion fluids have<br />been demonstrated in concentrations 0.016mg/ml and 0.64mg/ml.<br />Compatibility studies have been undertaken in Polyvinyl Chloride infusion bags with Polyvinyl<br />Chloride administration sets, Polyethylene infusion bags, Type 1 glass bottles and Polypropylene<br />syringes. Dilutions of Ondansetron Injection in 10% Mannitol injection, Ringer&rsquo;s injection, 0.3%<br />Potassium Chloride and 0.9% Sodium Chloride injection, 0.3% Potassium Chloride and 5% Dextrose<br />Injection, 0.9% Sodium Chloride injection and 5% Glucose Injection have been demonstrated to be<br />stable in Polyvinyl Chloride infusion bags and Polyvinyl Chloride administration sets, Polyethylene<br />infusion bags, Type 1 glass bottles and Polypropylene syringes.<br />Compatibility with other drugs: Ondron may be administered by intravenous infusion using 0.9%<br />Sodium Chloride and 5% Dextrose injection at 1mg/hour, e.g. from an infusion bag or syringe pump.<br />The following drugs may be administered via the Y‐site of the Ondron giving set for Ondansetron<br />concentrations of 16 to 160micrograms/ml (e.g. 8mg/500ml and 8mg/50ml respectively);<br />Cisplatin: Concentrations up to 0.48mg/ml (e.g. 240mg in 500ml) administered over one to eight<br />hours.<br />Carboplatin: Concentrations in the range 0.18mg/ml to 9.9mg/ml (e.g. 90mg in 500ml to 990mg in<br />100ml), administered over ten minutes to one hour.<br />Etoposide: Concentrations in the range 0.14mg/ml to 0.25mg/ml (e.g. 72mg in 500ml to 250mg in 1<br />litre), administered over thirty minutes to one hour.<br />Ceftazidime: Doses in the range 250mg to 2000mg reconstituted with Water for Injection BP as<br />recommended by the manufacturer (e.g. 2.5ml for 250mg and 10ml for 2g Ceftazidime) and given as<br />an intravenous bolus injection over approximately five minutes.<br />Cyclophosphamide: Doses in the range 100mg to 1g, reconstituted with Water for Injection BP, 5ml<br />per 100mg Cyclophosphamide, as recommended by the manufacturer and given as an intravenous<br />bolus injection over approximately five minutes.<br />Doxorubicin: Doses in the range 10‐100mg reconstituted with Water for Injection BP, 5ml per 10mg<br />Doxorubicin, as recommended by the manufacturer and given as an intravenous bolus injection over<br />approximately 5 minutes.</p><p>Dexamethasone: Dexamethasone Sodium Phosphate 20mg may be administered as a slow<br />intravenous injection over 2‐5 minutes via the Y‐site of an infusion set delivering 8 or 16mg of<br />Ondansetron diluted in 50‐100 ml of a compatible infusion fluid over approximately 15 minutes.<br />Compatibility between Dexamethasone Sodium Phosphate and Ondansetron has been<br />demonstrated supporting administration of these drugs through the same giving set resulting in<br />concentrations in line of 32 microgram ‐ 2.5mg/ml for Dexamethasone Sodium Phosphate and 8<br />microgram &ndash; 0.75mg/ml for Ondansetron.<br />The solution is to be visually inspected prior to use (also after dilution). Only clear solutions<br />practically free from particles should be used.<br />The diluted solutions should be stored protected from light.<br />Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accord Healthcare Limited
Sage House,
319 Pinner Road,
North Harrow,
Middlesex, HA1 4HF,
United Kingdom
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2018 (SA)
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>